Special Collections from Antibody Therapeutics
Antibody Therapeutics is a peer-reviewed, online, fully open access journal that provides a forum for the publication of the latest advances and challenges in the discovery, research, development, manufacturing, and methodology of therapeutic antibodies for the global scientific community.
The journal regularly holds calls for papers for upcoming special collections and the results of which are published in the following article collections. For the most recent calls and a chance to publish your research in these timely antibody topics, please see our calls for papers page.
Collection
Chung-Ming (CM) Hsieh, Vice President, Protein Therapeutics, Gilead Sciences; Yue Liu, Founder and President, Ab Studio; Zhaohui Sunny Zhou, Professor, Northeastern University

AntibodyPlus
TM was introduced by the Chinese Antibody Society (CAS) in 2021 to better reflect the overwhelming growth of antibody-based therapeutics. The AntibodyPlus
TM concept describes protein therapeutics as well as genetic medicines that encode them that comprise components derived from antibodies and one or more effector modules, e.g., small molecules, nucleic acids, peptides, proteins, and cells to enhance their therapeutic efficacy in many different disease areas. We organized this AntibodyPlus
TM special collection to highlight their compelling values and the technology trends that enable them.
Collection
Guest Editors: Dr. Antonella Antignani and Dr. David FitzGerald at National Cancer Institute of National Institutes of Health

Treating cancer with agents that target surface antigens or receptors is made possible by the selective use of cell-reactive antibodies. To be effective, antibodies are frequently modified by attaching, either chemically or genetically, a cytotoxic agent and most cytotoxic agents are selected from among highly potent drugs or protein toxins. Antibody binding transports the cytotoxic agent to the cell interior where intracellular processing releases the payload resulting in cell death. Cytotoxic agents include tubulin-disrupting drugs, DNA damaging compounds and protein toxins (of bacterial or plant origin) that inhibit protein synthesis. On malignant cells, surface targets include differentiation antigens, oncofetal antigens and receptors that are overexpressed or mutated. Some target cells are ‘non-malignant’ but contribute to oncogenesis via immune suppression. These ‘non-malignant’ cells (e.g. T-regs) can also be targets for antibody-derived cytotoxic agents. The goal of using antibodies for delivery of cytotoxics is to ensure that preferential binding on cancer cells limits damage to normal cells. However, resistance to antibody-related treatments which arises in several different ways is still possible and must be addressed to achieve durable responses in cancer patients.
Collection
Guest Editors: Jianlin (Jim) Xu, PhD, Scientific Director in Global Upstream Process Development at Bristol Myers Squibb in Devens, Massachusetts, USA and Wei Zhang, PhD, Downstream Process Group Head of Bioprocessing Technology Institute, A*STAR in Singapore

Bispecific antibodies (bsAbs) are a fast-growing group of therapeutic antibodies. Although US FDA has approved only three bsAbs as of June, 2021, nearly 160 bsAbs are in clinical trials, accounting for nearly 20% of the clinical antibody pipeline, based upon the data from Nature Reviews Drug Discovery. The discovery and protein engineering techniques of bsAbs are now relatively advanced. However, the development of bsAbs still faces many challenges in Chemistry, Manufacturing, and Controls (CMC). As invited guest editors for Antibody Therapeutics, we organized this special issue with a focus upon bsAb CMC.